

## **Product datasheet for SR301301**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **DUSP7 Human siRNA Oligo Duplex (Locus ID 1849)**

**Product data:** 

**Product Type:** siRNA Oligo Duplexes

Purity: HPLC purified

Quality Control: Tested by ESI-MS

Sequences: Available with shipment

**Stability:** One year from date of shipment when stored at -20°C.

# of transfections: Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final

conc. 10 nM).

**Note:** Single siRNA duplex (10nmol) can be ordered.

**RefSeq:** <u>NM 001947</u>

UniProt ID: Q16829

**Synonyms:** MKPX; PYST2

Components: DUSP7 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 1849)

Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol

Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml

Summary: Dual-specificity phosphatases (DUSPs) constitute a large heterogeneous subgroup of the type

I cysteine-based protein-tyrosine phosphatase superfamily. DUSPs are characterized by their ability to dephosphorylate both tyrosine and serine/threonine residues. DUSP7 belongs to a class of DUSPs, designated MKPs, that dephosphorylate MAPK (mitogen-activated protein kinase) proteins ERK (see MIM 601795), JNK (see MIM 601158), and p38 (see MIM 600289) with specificity distinct from that of individual MKP proteins. MKPs contain a highly conserved C-terminal catalytic domain and an N-terminal Cdc25 (see MIM 116947)-like (CH2) domain.

MAPK activation cascades mediate various physiologic processes, including cellular

proliferation, apoptosis, differentiation, and stress responses (summary by Patterson et al.,

2009 [PubMed 19228121]).[supplied by OMIM, Dec 2009]







## Performance Guaranteed:

OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).